IOVA

Iovance Biotherapeutics Stock Analysis

AI Rating

Fair
  • Quality2/10
  • Growth↑ 5/10
  • Value↓ 0/10
Iovance Biotherapeutics sales and earnings growth
IOVA Growth
Neutral
  • Revenue Y/Y↑ 60.60%
  • EPS Y/Y↑ 14.84%
  • FCF Y/Y↑ 7.64%
Iovance Biotherapeutics gross and profit margin trends
IOVA Profitability
Neutral
  • Gross margin ↑ 34.30%
  • EPS margin↓ -148.40%
  • ROIC 5Y↓ -112.76%
Iovance Biotherapeutics net debt vs free cash flow
IOVA Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Iovance Biotherapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗